It looks like yesterday we reported about the new C-19 variant from South Africa. But, within hours, Big Pharma emerged with the vaccine for the new mutation.
Novavax Inc (NVAX.O) said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.
The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.
Novavax’s vaccine received its first emergency use approval earlier this month in Indonesia followed by the Philippines. Other vaccine developers, including Germany’s BioNTech SE and Johnson & Johnson, have said they are testing the effectiveness of their shots against the new variant, which is named Omicron by the World Health Organization
And, last night we reported that companies were ready to test the vaccine within the next two weeks.
The Conservative Treehouse reported:
Wow, 72 hours ago no one even heard the name Omicron variant. Now, in less than three days, a variant has been identified, global travel has been halted, states of emergency have been declared, and now we see a pharmaceutical company announcing the variant-specific vaccine trial that will begin in the U.S. in a few weeks. This government relationship with Big Pharma is certainly generating some fast action, eh?
Is this a miracle from modern medicine, or is it something else?
Novavax Developing Vaccine Against Variant That Appeared 72 Hours Ago – Will Be Ready in Two Weeks, Already in Emergency Use Trials in Indonesia and Phillipines
November 26, 2021 | Sundance | 442 Comments
Wow, 72 hours ago no one even heard the name Omicron variant. Now, in less than three days, a variant has been identified, global travel has been halted, states of emergency have been declared, and now we see a pharmaceutical company announcing the variant specific vaccine trial that will begin in the U.S. in a few weeks. This government relationship with Big Pharma is certainly generating some fast action, eh?
If a person was cynically inclined; while knowing governments’ need to control inflation yet cannot raise interest rates or stop purchasing debt because current legislative spending continues – a remarkable control option would be to halt demand; and a person might think this was suspicious, or something.
Nov 26 (Reuters) – Novavax Inc said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.
The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.
Novavax’s vaccine received its first emergency use approval earlier this month in Indonesia followed by the Philippines. Other vaccine developers, including Germany’s BioNTech SE and Johnson & Johnson, have said they are testing the effectiveness of their shots against the new variant, which is named Omicron by the World Health Organization
Hope this helps....
The modern medicine
It looks like yesterday we reported about the new C-19 variant from South Africa. But, within hours, Big Pharma emerged with the vaccine for the new mutation.
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
Reuters shared yesterday:
Novavax Inc (NVAX.O) said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.
The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.
Novavax’s vaccine received its first emergency use approval earlier this month in Indonesia followed by the Philippines. Other vaccine developers, including Germany’s BioNTech SE and Johnson & Johnson, have said they are testing the effectiveness of their shots against the new variant, which is named Omicron by the World Health Organization
And, last night we reported that companies were ready to test the vaccine within the next two weeks.
The Conservative Treehouse reported:
Wow, 72 hours ago no one even heard the name Omicron variant. Now, in less than three days, a variant has been identified, global travel has been halted, states of emergency have been declared, and now we see a pharmaceutical company announcing the variant-specific vaccine trial that will begin in the U.S. in a few weeks. This government relationship with Big Pharma is certainly generating some fast action, eh?
Is this a miracle from modern medicine, or is it something else?
Novavax Developing Vaccine Against Variant That Appeared 72 Hours Ago – Will Be Ready in Two Weeks, Already in Emergency Use Trials in Indonesia and Phillipines November 26, 2021 | Sundance | 442 Comments Wow, 72 hours ago no one even heard the name Omicron variant. Now, in less than three days, a variant has been identified, global travel has been halted, states of emergency have been declared, and now we see a pharmaceutical company announcing the variant specific vaccine trial that will begin in the U.S. in a few weeks. This government relationship with Big Pharma is certainly generating some fast action, eh?
If a person was cynically inclined; while knowing governments’ need to control inflation yet cannot raise interest rates or stop purchasing debt because current legislative spending continues – a remarkable control option would be to halt demand; and a person might think this was suspicious, or something.
Nov 26 (Reuters) – Novavax Inc said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.
The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.
Novavax’s vaccine received its first emergency use approval earlier this month in Indonesia followed by the Philippines. Other vaccine developers, including Germany’s BioNTech SE and Johnson & Johnson, have said they are testing the effectiveness of their shots against the new variant, which is named Omicron by the World Health Organization